PLOS ONE | https://doi.org/10.1371/journal.pone.0192068 March 9, 2018
Available in English, French, Chinese, Arabic, Russian
8 February 2021
Find here the latest information
The Fifty-first World Health Assembly,
Recalling resolutions WHA22.29, WHA25.55 and WHA28.54 on the prevention of blindness, and
WHA45.10 on disability prevention and rehabilitation; Aware of previous efforts and progress made in the global fight against infectious eye diseases, in particular trac...homa; Noting that blinding trachoma still constitutes a serious public health problem amongst the poorest populations in 46 endemic countries.
more
Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and
blindness. But the epidemiological situation has improved dramatically over the last two decades.... Community directed treatment with ivermectin has effectively brought the disease under control in most endemic areas where onchocerciasis is no longer a public health risk.
more
This report outlines the coordination and partnership between two key ministries (Education and Public Health) in Kenya, other line ministries, the private sector, NGOs and the community in implementing the first phase of a sub-national school-based deworming exercise. The areas targeted included Co...ast, Central, Western, Nyanza
and parts of Eastern provinces, covering over 45 districts in this first phase. The SBD programme is guided by the National School Health Policy and Guidelines launched in 2009.
more
The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration of IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan ...will also help strengthen health systems at community level while implementing CDI wlll help scale-up interventions agalnst other NTDs to the benefit of the wider national health systems.
more
Health communication has proven to play a crucial role in addressing diseases such as dengue, Zika and chikungunya, for which there are no definitive or easily accessible vaccines. In this context, this discipline becomes a fundamental tool to promote the change behavior and promote preventive pract...ices that reduce the transmission of these diseases. By not having a definitive medical solution, accurate and timely information, effectively disseminated through educational campaigns, media and communication channels public health, can significantly influence individual and community actions to control the spread of these mosquito-borne viruses. The accumulated research around the threat of the aforementioned arboviral diseases brings together a series of recommendations around specific communication activities, such as disseminating timely and accurate information that integrates public health concerns and the needs of information of the population, especially vulnerable groups such as women of childbearing age, pregnant women and health workers.
more
A Guide for Low Resource Situations
The manufacturing process is one of the key steps where quality control is required to ensure quality of medicinal products, including herbal medicines. Good manufacturing practices (GMP) is one of the most important tools for this measure.
This guideline provides global, evidence-informed recommendations on a number of specific issues related to the management of severe acute malnutrition in infants and children, including in the context of HIV.
This manual provides a practical method for determining the pharmacovigilance indices. It is designed to be simple and can be understood by any worker in pharmacovigilance without formal training in monitoring and evaluation. Pharmacovigilance as a medical discipline is crucial in preventing medicin...e-related adverse effects in humans, promoting patient safety, and the rational use of medicines. The indicators proposed in this manual are based on the expected functions of pharmacovigilance centres as described in the WHO Mimimum Requirements for a Functional Pharmacovigilance System (1) (see Annex 1 of the manual).
more
MMC Briefing Paper, February 2021